Articles tagged with Colorectal Cancer
Researchers found that a combination of symptom and high-level viral rebound after untreated COVID-19 infection is rare, occurring in only 3 percent of study participants. This suggests that accounting for underlying rates of symptom relapse is crucial when evaluating antiviral treatment effects.
Researchers discovered that combining ferroptosis induction with immune checkpoint inhibition reduces liver tumour growth and metastases, offering a promising new approach for treating liver cancer
Replacing red and processed meat with Quorn's mycoprotein reduces intestinal genotoxins, a risk factor for bowel cancer, and increases beneficial gut bacteria. The study found significant reductions in harmful chemicals and improvements in gut health in participants consuming the mycoprotein diet.
Researchers at Uppsala University developed a prognostic method using a combination of immune cells to provide clearer disease prognoses and predict which patients will respond best to immunotherapy. The method was shown to be associated with patient fate in several types of cancer.
A study published in CANCER found that people's defensive beliefs can prevent them from taking at-home stool tests for colorectal cancer screening. Individuals who reacted defensively were more likely to believe that a healthy lifestyle or regular bowel movements mean they don't need to be screened.
Researchers found that arginine levels are limited in human cancers, prompting cancer cells to manipulate proteins to take up the amino acid. Starving cancer cells of arginine may lead to mutations that make them more recognizable to the immune system.
A phase 2 clinical trial combining immunotherapy and targeted therapy showed a 24.3% confirmed response rate and 5-month median progression-free survival among patients with BRAF V600 mutations. The treatment also demonstrated increased durability, with 57% of patients remaining on treatment for more than 6 months.
A UK study found that people with type 2 diabetes have substantially higher cancer mortality rates than the general population. Breast cancer mortality in younger women with T2D is rising, highlighting the need for extended screening, better management of diabetes and its complications, and improved cancer treatments.
A combination of two novel immunotherapy drugs has shown promising clinical activity in treating patients with refractory metastatic colorectal cancer. The study found that 23% of patients had a tumor reduction, and the disease control rate was 76%. The treatment was well-tolerated, but adverse events were common.
A team at Harvard Medical School has created large-scale 2D and 3D spatial maps of colorectal cancer, layering molecular information on top of histological features. The maps reveal the interconnectedness of traditional isolated structures in colorectal cancer, allowing researchers to explore differences within individual tumors.
A study of over 32,000 individuals reveals low follow-up colonoscopy rates among average-risk populations, with socioeconomic factors and the COVID-19 pandemic contributing to these gaps. These findings highlight opportunities for targeted interventions by clinicians and healthcare systems to improve colorectal cancer screening outcomes.
Researchers discovered that pre-surgery immunotherapy significantly improved patient outcomes for locally advanced colorectal cancer. The treatment showed substantial longer survival benefits, including low recurrence rates, in patients with mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) CRC.
A new University of Kentucky Markey Cancer Center study found that people in Kentucky's Black communities may not be aware of all available colorectal cancer screening options, particularly stool-based tests. Regular screening beginning at age 45 is key to preventing and finding colorectal cancer early.
Researchers developed predictive models using serum microRNAs to identify patients at risk of requiring early palliative care. The study used serum samples from 178 patients with various types of cancer and found that miRNA-based models had higher accuracy than clinical models in predicting referral to a palliative care unit.
A new software developed by researchers at Cold Spring Harbor Laboratory can accurately infers continental ancestry from tumor DNA and RNA. This technology has the potential to lead to more targeted and personalized cancer treatments by identifying genetic connections between cancer and race or ethnicity.
Researchers found that AI-assisted colonoscopy significantly improved adenoma detection rates in patients with Lynch syndrome, detecting flat adenomas more effectively than standard examinations. The study suggests that AI-assisted real-time colonoscopy is a promising approach to optimize endoscopic surveillance for LS patients.
Research from Michigan Medicine reveals that high levels of ammonia in colon tumors can lead to reduced T cell growth and immunotherapy resistance. A study published in Cell Metabolism found that using an FDA-approved drug to lower ammonia levels made tumors more sensitive to treatment.
A comprehensive analysis of over 100,000 colorectal cancer cases identified 100 new genetic risk factors strongly linked with the disease. These findings could help clinicians determine who's at highest risk for early detection and potentially identify candidates for preventive treatments.
A massive international data analysis uncovered hundreds of signals for new treatment and prevention targets in colorectal cancer. The study identified 250 independent risk associations, including 50 newly discovered ones, through analyzing genomic, transcriptomic, and methylomic data.
Researchers discovered PDGF cross-signaling through alternative receptors in colorectal cancer cells, enabling bypassed signaling. This finding supports anti-PDGF therapy as a combination strategy alongside VEGF and EGF targeting.
A new study has identified a potential therapy for metastatic colon cancer by targeting the molecule hyaluronan, which accumulates in tumors and shuts down immune cells that can kill tumor cells. The experimental therapy, hyaluronidase, shrinks tumors and allows immune cells to attack tumor cells.
The National Cancer Institute awards $10.5 million to USC's Division of Biostatistics to develop statistical methods for uncovering new risk factors associated with cancer by integrating large volumes of health, genomic, and exposure data. The project aims to provide new insights into complex biological processes and discoveries of nov...
Researchers found that muscle wasting severity is related to the type, size and location of tumors in mice, with different tumors causing varying levels of wasting. The study's findings have crucial implications for understanding how different cancers affect muscle mass and developing effective treatments.
Researchers discovered three essential amino acids - leucine, valine, and tryptophan - as potential metabolic biomarkers for HCC. The study used metabolomics to analyze the differences in tumor and non-tumor tissue metabolomes, revealing striking differences that could aid in diagnosis.
A new study found that a three-year interval between screenings using non-invasive multi-target stool DNA testing is clinically appropriate for individuals with average risk of colorectal cancer. The study, led by Thomas F. Imperiale, M.D., identified no colorectal cancers in participants after an initial negative test.
Eating a diet rich in whole grains, vegetables, and legumes is associated with a reduced risk of colorectal cancer in men. The study found that men who consumed the highest amounts of healthy plant-based foods had a 22% lower risk of colorectal cancer compared to those who ate the lowest amounts.
Researchers at Goethe University Frankfurt found that dying colon cancer cells release ATP to neighboring tumor cells, activating a survival signaling pathway. Interrupting this communication can significantly increase the effectiveness of chemotherapy against resistant tumors.
Population-based cancer screening rates declined during the pandemic, only to recover rapidly in initial stages; however, long-term follow-up reveals ongoing gaps in preventive care. The study suggests that prolonged disruptions in screening can have lasting effects on public health.
The ESMO Asia Congress 2022 will focus on the latest scientific and clinical advances in oncology, with a special emphasis on the Asia-Pacific region. Media representatives can register for coverage through the official media registration form.
Researchers at the Fred Hutchinson Cancer Center discovered that oral bacteria like Fusobacterium nucleatum can infiltrate tumors, influencing their growth and response to treatment. The findings suggest a link between oral health and cancer, highlighting the potential for microbiome-based therapies to combat cancer.
A study of 11,945 people found that those with type 2 diabetes are more likely to be diagnosed with advanced cancer if the condition is not screened for routinely. Researchers identified a 26% increased risk of metastasis in patients with pre-existing type 2 diabetes.
Researchers found that excessive iron accumulation accelerates tumor growth in F. nucleatum-positive colorectal cancer by enhancing inflammatory responses in immune cells, promoting interpatient prognostic variability. Iron levels also modulate macrophage expression profiles, transforming them into pro-tumor cells expressing CCL8.
A new online personal health record tool has significantly increased adherence by colorectal cancer survivors to national guidelines. The tool, developed by the Regenstrief Institute and other researchers, provides a patient-centered platform for tracking follow-up care, managing symptoms, and connecting with healthcare providers.
Researchers at UNIGE have discovered a way to overcome resistance to chemotherapy in colorectal cancer, using an optimized combination of tyrosine kinase inhibitors. This breakthrough opens up new avenues for developing targeted therapies that can effectively treat patients with low five-year survival rates.
A new study reveals that urolithin A from pomegranates can rejuvenate T cells by recycling and renewing mitochondria, enhancing their ability to fight tumors. The researchers plan to investigate the application of urolithin A in clinical trials for colorectal cancer.
A meta-analysis of 410 articles from 68 countries found that patients in lower-income countries take up to four times longer to initiate care for cancer treatment. Cancers causing non-specific symptoms, such as myeloma and colorectal cancer, typically take the longest to diagnose.
A new approach combines an immunotherapy agent with a molecular delivery system that targets tumor acidity, successfully eradicating colorectal tumors in mice. The researchers believe this method may increase the effectiveness of STING agonist therapy for cancer patients.
Researchers identified urolithin A as a compound that improves function of immune cells against cancer. The study found that urolithin A induces mitophagy in T cells, recycling and renewing mitochondria to enhance tumor-fighting capabilities.
A Singapore research team has validated a cancer diagnostic assay designed with Asian-centric biomarkers, showing high precision and sensitivity in measuring four major classes of biomarkers. The assay's performance was validated with clinical specimens, indicating its promise for reliable deployment in a clinical setting.
The American College of Physicians recommends increasing funding for health services and prioritizing health promotion in Indigenous communities. Community-driven public policy is also necessary to address historical trauma, social determinants of health, and inadequate access to healthcare services.
Researchers found that certain fungal species in tumors are linked to inflammation and reduced cell-to-cell adhesion, features associated with late-stage cancer spread. High levels of these fungi may serve as biomarkers for metastasis risk and lead to more effective treatment choices.
A UTHealth Houston study found regional disparities in cancer screening rates tied to social vulnerability, with lower rates in more vulnerable counties. The study analyzed 3,141 US counties and discovered significant differences in breast, cervical, and colorectal cancer screenings.
A study of 3,141 US counties found that counties with higher social vulnerability had lower rates of recommended breast, cervical, and colorectal cancer screenings. The findings suggest that addressing social determinants of health may be crucial for improving cancer screening rates.
The TTUHSC team will provide no-cost colorectal cancer screening and colonoscopies to underinsured and uninsured people living in South Plains region counties. The FIT-STOP program aims to find signs of early-stage colorectal cancer to prevent treatment needs, leveraging existing relationships with partners.
A new predictive biomarker, RNF43 mutations, has been identified as a significant predictor of response to anti-BRAF/EGFR combinatory therapy in patients with microsatellite stable BRAF V600E metastatic colorectal cancer. This biomarker is associated with improved progression-free and overall survival rates.
A cohort study found that endoscopists performing colonoscopies in FIT-based screening programs should aim for markedly higher ADRs compared to primary colonoscopy screening. The study suggests that high ADRs are associated with lower colorectal cancer incidence and mortality. Researchers recommend using ADR targets, including differen...
The author suggests that individuals at average risk between 45 and 49 years old should consider non-invasive screening alternatives, such as fecal immunochemical tests or stool DNA testing. This approach would benefit others who need more invasive screening resources and reduce the strain on colonoscopy services.
A new combination immunotherapy regimen shows remarkable activity in metastatic colorectal cancer patients without liver metastases, achieving a response rate of 40% and median overall survival exceeding 20 months. The study's findings confirm the importance of the tumor microenvironment in shaping the response to immunotherapy.
In a Phase I/II trial, selpercatinib demonstrated a 44% objective response rate across multiple tumor types, including pancreatic and colorectal cancers. The study found responses regardless of cancer type or prior treatment history, confirming RET fusions as a tissue-agnostic target.
Two large studies found a link between high consumption of ultra-processed foods and increased risks of cardiovascular disease, bowel cancer, and death. The findings support policies limiting ultra-processed foods and promote eating unprocessed or minimally-processed foods for improved public health.
Researchers found a strong association between high ultra-processed food consumption and colorectal cancer risk in men, particularly those consuming processed meats. In contrast, no link was found for women, suggesting potential sex differences in the relationship between diet and cancer risk.
Researchers developed an algorithm to identify different regions within tumors using nearly 6,500 digital slide images. The algorithm can predict recurrence-free survival and help guide therapy for patients with colon cancer.
Researchers at Queen Mary University of London have found that increasing the blood level at which faecal blood testing triggers a colonoscopy invitation can reduce lives lost from bowel cancer. This approach is more effective than changing the gap between screening invitations.
Researchers found that using the drug erlotinib, which blocks a specific cancer pathway, led to a 30 percent reduction in polyps formed in patients with FAP. The study's findings suggest potential ways to prevent colorectal cancer in the general population at an earlier stage.
A study led by Toho University identified a glycan structure, Lewis glycans, on the cell surface that makes cancer cells vulnerable to TRAIL-induced death. Cancer cells highly expressing this structure are more sensitive to TRAIL therapy and can serve as a predictive biomarker.
A new UCI-led study reveals that the circadian clock's disruption can drive colorectal cancer progression through genetic mutations and increased tumor growth. The study found that both environmental and genetic disruptions of the circadian clock contribute to APC loss of heterozygosity, a critical factor in CRC development.
A recent clinical trial led by Massachusetts General Hospital validated a strategy for increasing shared decision-making about colorectal cancer screening in older patients. Brief physician training plus reminders resulted in patients reporting higher quality conversations, with more discussing their preferences and having more options...
A new study by Tokyo University of Science researchers reveals that dendritic cell immunoreceptor (DCIR) plays a crucial role in the development of colorectal tumors. Blocking DCIR may prevent ulcerative colitis and colon cancer, offering a potential therapeutic target for treating these diseases.
Researchers investigated the effects of neoadjuvant chemoradiotherapy on CD8+ tumor-infiltrating lymphocytes, PD-L1, and mucin expression in rectal cancer patients. The study found that nCRT exposure was associated with higher mucin expression and a non-significant difference in PD-L1 expression, suggesting an immunosuppressive phenotype.
A new study from Duke University suggests that consuming more fiber can lead to improved gut health, regardless of the specific supplement used. Participants who had been eating the least amount of fiber before the study showed the greatest benefit from supplements.